SS-31 (Elamipretide)

01 What is SS-31 (Elamipretide)?

SS-31 is a synthetic tetrapeptide that does something almost no other compound can: it penetrates the inner mitochondrial membrane and binds directly to cardiolipin, a phospholipid essential for electron transport chain function. This is not a metaphor — SS-31 physically enters your mitochondria and stabilises their energy-producing machinery. Why does this matter? Mitochondrial dysfunction is increasingly recognised as a root cause of ageing, heart failure, kidney disease, neurodegenerative conditions, and metabolic decline. As you age, cardiolipin degrades, electron transport becomes leaky, reactive oxygen species (ROS) increase, and ATP production drops. SS-31 reverses this process at the source. Developed by Hazel Szeto at Weill Cornell Medicine, SS-31 (branded as Elamipretide) has progressed to Phase III clinical trials for Barth syndrome and has been studied in heart failure, age-related mitochondrial decline, and acute kidney injury. This is not a fringe peptide — it has serious pharmaceutical backing.

02 How Does It Work?

SS-31 has a unique cell-penetrating structure (D-Arg-Dmt-Lys-Phe-NH2) that allows it to concentrate 1,000-5,000x inside mitochondria relative to the cytoplasm. Once inside, it: 1. Binds cardiolipin on the inner mitochondrial membrane. 2. Stabilises cytochrome c interactions, improving electron transport efficiency. 3. Reduces electron leak, decreasing mitochondrial ROS production by 40-60%. 4. Restores ATP synthesis to youthful levels. 5. Prevents mitochondrial permeability transition pore opening (which triggers cell death). The net effect is rescued mitochondrial function — more energy, less oxidative damage, reduced cellular stress.

03 What Does The Research Say?

Phase III trial for Barth syndrome (a genetic mitochondrial disease) showed improved cardiac function and exercise capacity. Phase II trials in heart failure showed improved left ventricular function. Preclinical studies show reversal of age-related decline in skeletal muscle, kidney function, and cardiac output. A landmark 2018 study in aged mice showed SS-31 reversed age-related mitochondrial dysfunction in skeletal muscle within just 8 weeks, restoring mitochondrial energetics to near-youthful levels. This is one of the most impressive demonstrations of mitochondrial rejuvenation in the ageing literature. Human ageing trials are not yet complete, but the preclinical evidence is among the strongest for any anti-ageing compound currently in development.

04 Reported Dosages

Clinical trials use 4mg/hour IV infusion or 40mg subcutaneous injection. Research/biohacking community reports: 5-50mg subcutaneous daily (protocols vary widely). This is a clinical-stage pharmaceutical — dosing should only occur under medical supervision. DISCLAIMER: SS-31/Elamipretide is an investigational drug. Not approved for general use.

05 Side Effects & Risks

Clinical trials report injection site reactions, mild headache, and occasional nausea. Safety profile appears favourable in published trials. Long-term safety data is still being collected. As a mitochondria-targeted compound, off-target effects appear minimal because the peptide concentrates specifically in mitochondria rather than acting systemically.

06 Legal Status